Sanofi's Diabetes Sales Force Increase Not Due To Threat From Exubera Or Levemir, Exec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi attributes its increased detailing focus on the diabetes market to changing prescribing trends, not increased competition.